Ascelia Pharma wins the award for Best Life Science company in Malmö

2020-02-11

Ascelia Pharma AB (publ) (ticker: ACE) was yesterday evening awarded the price for best Life Science company in Malmö at the city’s prestigious annual corporate awards (Malmö Näringslivsgala). The price award follows Ascelia Pharma’s work on developing novel drug candidates that fill a distinct unmet medical need.

“We are very pleased and honored by the award that emphasises our diligent work to develop novel drugs that improve the life expectancy and quality of life for people living with cancer. As communicated earlier, we have opened sites for patient enrolment in our registration-enabling Phase III study for our lead drug candidate Mangoral and expect sales launch in 2022 in the US. To ensure continued successful development, we are expanding our company in Malmö”, said Magnus Corfitzen, CEO of Ascelia Pharma.

 

For more information, please contact:
Magnus Corfitzen, CEO
Email: moc@ascelia.com
Tel. 46 735 179 110

Mikael Widell, IR & Communications Manager
Email: mw@ascelia.com
Tel: +46 703 11 99 60

About Ascelia Pharma
Ascelia Pharma is an oncology-dedicated orphan drug development company located in Malmö, Sweden. The company’s strategy is to develop drugs, which target unmet medical needs, have an established mode of action and a relatively low development risk. Ascelia Pharma has two drug candidates – Mangoral® and Oncoral – currently under development.

Mangoral is a novel contrast agent for MR-scans and is ready for Phase III clinical studies. Mangoral is developed to improve the visualization of focal liver lesions (liver metastases) in patient with impaired kidneys that cannot tolerate current gadolinium contrast agents on the market. Oncoral is an oral chemotherapy tablet ready for Phase II for the treatment of gastric cancer. Ascelia Pharma is listed on Nasdaq Stockholm (ticker: ACE). For more information, please visit http://www.ascelia.com.

2020-03-05

Analysguiden/Carlsquare updates its view on Ascelia Pharma and raises target share price

Today Analysguiden/Carlsquare published an updated equity research report on Ascelia Pharma.  As part of their updated view, they raise their target share price to 41.90 kr from 34.80 kr.
2020-03-02

Issue and repurchase of series C shares for share saving program

Pursuant to the authorization granted by the annual general meeting on 14 November 2019, the board of directors of Ascelia Pharma AB (”Ascelia”) has resolved to issue and immediately thereafter repurchase  510,545 series C shares. The shares are issued and repurchased in accordance with the share saving program LTI 2019, which was adopted by the annual general meeting on 14 November 2019.
2020-02-20

Vator Securities: Ascelia Pharma: A rocket roll out is the key to success

February 20, 2020